Insulin-like growth factor-binding protein 5 mRNA (IGFBP-5 mRNA) (IGFBP-5 mRNA)

Insulin-like growth factor-binding protein 5 (IGFBP-5) mRNA is a therapeutic target primarily addressed using antisense technology to modulate the expression of the IGFBP-5 protein (UniProt P24593). IGFBP-5 is the most conserved member of the IGFBP family and plays a dual role in cellular signaling, acting both as a carrier that regulates the bioavailability of insulin-like growth factors (IGFs) and through IGF-independent mechanisms (PubMed: 25236568). In oncology, over-expression of IGFBP-5 is associated with the progression of various cancers to treatment-resistant states, such as castrate-resistant prostate cancer, by promoting cell survival and inhibiting apoptosis (PubMed: 24501019). Beyond cancer, IGFBP-5 is implicated in fibrotic diseases like systemic sclerosis and pulmonary fibrosis due to its role in stimulating extracellular matrix production (PubMed: 21828216). Therapeutic strategies, most notably the antisense oligonucleotide apatorsen (OGX-427), aim to downregulate IGFBP-5 expression to sensitize tumor cells to chemotherapy and inhibit disease progression (ClinicalTrials.gov: NCT01120470). By binding specifically to the IGFBP-5 mRNA sequence, these drugs trigger RNase H-mediated degradation, effectively reducing the levels of the pro-survival protein.

Other names

IBP5 mRNAIGF-binding protein 5 mRNAIGFBP5 mRNA

Antisense oligonucleotide-mediated mRNA degradation via RNase H activation, leading to decreased protein expression.